Arkolith/Insider Trading/NAMS/Form 4

Davidson Michael H.

Chief Executive Officer, DirectorNewAmsterdam Pharma Co N.V. (NAMS) · full profile →Form 4 · filed Jan 9, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 7, 2026Grant(A)81K——460K
Jan 7, 2026Sell(S)12K——379K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 7, 2026Grant(A)364K—$0364K

Transaction Codes

A
Grant / award
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-009272) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML